NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Income from Continuing Operations of 48441000.0 for Q1 2026, down 22.55% on a YoY basis from 62546219.16 in Q1 2025, and up 35.35% sequentially from 74923000.0 in Q4 2025.
NewAmsterdam Pharma (NAMS) Income from Continuing Operations (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Income from Continuing Operations data on file, last reported at 48441000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 22.55% year-over-year to 48441000.0; the trailing twelve-month figure through Mar 2026 stood at 212733000.0 (down 13.54% YoY), and the FY2025 full-year result was 202517000.0, up 16.18% from the prior year.
- Income from Continuing Operations grew to 48441000.0 in Q1 2026, from 74923000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 58087000.0 in Q4 2023 to a low of 93767000.0 in Q1 2024.
- A 4-year average of 43324076.92 and a median of 42018000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 64.68% in 2024 and sank 332.54% in 2025, its largest moves.
- Tracing NAMS's Income from Continuing Operations over 4 years: stood at 58087000.0 in 2023, then slumped by 258.69% to 92177000.0 in 2024, then climbed by 18.72% to 74923000.0 in 2025, then surged by 35.35% to 48441000.0 in 2026.
- Business Quant data shows NAMS's Income from Continuing Operations at 48441000.0 in Q1 2026, 74923000.0 in Q4 2025, and 72005000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -48.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.44 Mn |
| Dec 31, 2025 | -74.92 Mn |
| Sep 30, 2025 | -72.01 Mn |
| Jun 30, 2025 | -17.36 Mn |
| Mar 31, 2025 | -39.53 Mn |
| Dec 31, 2024 | -92.18 Mn |
| Sep 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -39.01 Mn |
| Mar 31, 2024 | -93.77 Mn |
| Dec 31, 2023 | 58.09 Mn |
| Sep 30, 2023 | -47.13 Mn |
| Jun 30, 2023 | -38.29 Mn |
| Mar 31, 2023 | -42.02 Mn |